OPTN
$3.78
Optinose
$.15
4.13%
OPTN
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.56)
Revenue:  $14.69 Mil
Thursday
Nov 5
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Tuesday, August 4, 2020

What do you expect when OPTN reports earnings?
Beat
Meet
Miss

Where is OPTN's stock price going from here?
Up
Flat
Down
Stock chart of OPTN
Analysts
Summary of analysts' recommendations for OPTN
Score
Grade
Pivots
Resistance
$4.60
$4.43
$4.10

$3.93

Support
$3.60
$3.43
$3.10
Tweet
Growth
Description
OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA.